Brontictuzumab

Drug Profile

Brontictuzumab

Alternative Names: Anti-Notch 1; Anti-Notch 1 monoclonal antibody; OMP-52M51

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Developer OncoMed Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Notch-1 receptor antagonists; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer; Solid tumours
  • Clinical Phase Unknown Adenocarcinoma
  • Discontinued Haematological malignancies

Most Recent Events

  • 17 Apr 2017 OncoMed Pharmaceuticals terminates a phase-I clinical trial in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03031691)
  • 20 Jan 2017 Phase-I clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03031691)
  • 03 Dec 2016 Additional safety and efficacy data from a phase Ia trial in Solid tumours (Treatment-resistant, Second-line therapy or greater) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top